APRIL^-/- and BLyS^-/- lymphocyte proliferation significantly decreased when challenged with alloantigen. by Natalie M. Bath (6316517)

Encapsulation efficiency significantly decreases with increasing starting bacterial concentration. by Kelly C. Freudenberger Catanzaro (6701789)

MAF1 protein expression is significantly decreased in luminal, HER2-positive, and TNBC breast cancer subtypes. by Stephanie Cabarcas-Petroski (9631636)

Subjects:

Characteristics of patients who decreased their screen time by more than 60 minutes after the challenge. by Annaëlle Le Steunf (19838110)

Transcriptionally-inferred PI3K pathway activation and breast tumor stemness/grade exhibit significant, positive association. by Ralitsa R. Madsen (11681590)

Metadata supporting the published article: Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer by Olga Kantor (9119030)

KCNK1 overexpression is significantly associated with breast cancer cells invasion and metastasis markers. by Xiangchan Hou (18864991)

Subjects:

Variants of uncertain significance. by Ghada Al-Kafaji (12054792)

Subjects:

Significantly decreased necrosis observed on wheat leaves inoculated with <i>ΔZtknr4</i>. by Erika Kroll (20537020)

Expression and clinical significance of PFKP in breast cancer. by Danna Yeerken (8911448)

Temperature challenge protocol. by Kevin D. Gaitonde (15411707)

Subjects:

Texture features with statistically significant differences between HER2 2+ positive and negative patients for subtraction images. by Lirong Song (458651)

A 71-year-old woman with true-positive bone metastases. by Jeanette Ansholm Hansen (11726084)

A 54-year-old woman with true-positive bone metastases. by Jeanette Ansholm Hansen (11726084)

Metformin/rifampicin combination decreases <i>S</i>. <i>aureus</i> load and persisters in Mice. by Xiao-Qi Lin (9548375)

Image_1_Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.tif by Yu Tang (343157)

“…Background<p>After early-line (first- and second-line) endocrine therapy, hormone-receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBCs) become resistant to endocrine therapy. …”

Image_2_Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.tif by Yu Tang (343157)

“…Background<p>After early-line (first- and second-line) endocrine therapy, hormone-receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBCs) become resistant to endocrine therapy. …”

Table_1_Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.docx by Yu Tang (343157)

“…Background<p>After early-line (first- and second-line) endocrine therapy, hormone-receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBCs) become resistant to endocrine therapy. …”

KCNK1 and downstream proteins are positively correlated in clinical breast cancer samples. by Xiangchan Hou (18864991)

Subjects:

Prenatal LPS induces sickness behaviour and decreases maternal and predatory behaviours after an LPS challenge by T. Mendes-Lima (8273940)

“…</p> <p><b>Results:</b> Showed that: (1) relative to the S + S group, the LPS + S group showed decreased MB and slightly increased PB, without inducing sickness behaviour; (2) the LPS + LPS group showed decreased MB but few effects on PB; (3) there was increased sickness behaviour associated with increased TNF-alpha serum levels in the LPS + LPS group; (4) a significant increase in GFAP expression was observed in both LPS groups, which was greater in the LPS + LPS group and (5) no differences in the corticosterone of all groups.…”